Archive for Daily News

AMGN additions to the Pipeline Database and FDA Calendar

Jan 28, 2015 No Comments by

Latest updates to the Company Pipeline Database for January 27, 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Link Text Updated AMGN 158.89 Blinatumomab Acute Lymphoblastic Leukemia PDUFA PDUFA May 19, 2015. Priority review 1/28/2015 AMGN 158.89 ABP 501 (adalimumab) Moderate-to-severe rheumatoid arthritis Phase 3 Phase 3 data due […]

Daily News Read more

RMTI receives FDA Approval + updates for BCRX GEVA HTBX

Jan 26, 2015 No Comments by

Latest updates to the Company Pipeline Database for January 26, 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Link Text Updated BCRX 11.33 BCX4161 – OPuS-2 Hereditary angioedema Phase 2b Phase 2b data due by end of 2015 1/27/2015 GEVA 120.92 SBC-103 Mucopolysaccharidosis IIIB Phase 1/2 Phase 1/2 trial […]

Daily News Read more

Large cap PDUFA dates have been now added to BioPharmCatalyst. 20 in total today.

Jan 26, 2015 No Comments by

20 PDUFA dates from mainly large cap companies have been added to the Company Pipeline Database and FDA Calendar. Previously, BioPharmCatalyst has focused on providing information more small and mid-cap companies but due to readership demand, large cap companies that have upcoming PDUFA dates will now appear in the database. A decision whether or not to also […]

Daily News Read more

NPSP FDA Approval. KYTH Advisory Committee Meeting + PGNX resumes Phase 2 trial

Jan 24, 2015 No Comments

Latest updates to the Company Pipeline Database for January 23, 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Link Text Updated KYTH 35.28 ATX-101 Reduction of Localized Subcutaneous Fat in the Submental Area PDUFA PDUFA May 13 2015. Advisory Committee Meeting March 9 2015 1/25/2015 NPSP 45.64 Natpara Hypoparathyroidism […]

Read more

CYTR and MDVN release clinical data. ALXA initiates Phase 2 trial

Jan 22, 2015 No Comments

Latest updates to the Company Pipeline Database for January 22, 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Link Text Updated ALXA 2.07 AZ-002 Acute repetitive seizures Phase 2 Phase 2 initiated late Jan 2014 1/23/2015 CYTR 3.01 Aldoxorubicin Cancer – soft tissue sarcomas first line Phase 2b Overall […]

Read more

Distinct lack of clinical news this week – updates for OCUL and CYTR

Jan 22, 2015 No Comments

There has been a noticeable lack of major clinical news over the last couple days following the JPM Conference last week and looking forward to the 4Q earnings season in a couple weeks. Latest updates to the Company Pipeline Database from January 20 and 21, 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker […]

Read more

Latest updates for CUR TGTX TNXP

Jan 16, 2015 No Comments

Latest updates to the Company Pipeline Database from January 15, 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Link Text Updated CUR 2.89 NSI-566 Amyotrophic lateral sclerosis (Lou Gehrig’s) Phase 2 Phase 2 data are due LATE 1Q or EARLY 2Q 2015 according to Jan 2015 presentation. 1/16/2015 TGTX […]

Read more

ETRM receives FDA Approval. CUR Phase 2 ALS data due 2Q. OPK NDA filing update + RGDO BCRX news

Jan 15, 2015 No Comments

Latest updates to the Company Pipeline Database from January 14, 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Text Updated BCRX 11.41 BCX4161 – OPuS-2 Hereditary angioedema Phase 2b Phase 2b data due by end of 2015 1/15/2015 CUR 3.09 NSI-566 Amyotrophic lateral sclerosis (Lou Gehrig’s) Phase 2 Phase […]

Read more

Latest pipeline updates. 40 in total!

Jan 13, 2015 No Comments

Latest updates to the Company Pipeline Database from January 12 and 13, 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Text Updated ATRS 2.46 VIBEX QuickShot Testosterone deficiency Phase 3 Phase 3 initiated July 2014. Final patient dosed Nov 2015. Top-line pharmacokinetic data due 2Q 2015 1/14/2015 CPRX 2.87 […]

Read more

ARGS Phase 2 trial fail. PTLA Phase 3 Andexanet alfa meets endpoint + updates from ORPN RIGL SAGE TXNP

Jan 09, 2015 No Comments

Latest updates to the Company Pipeline Database from January 9, 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Text Updated ARGS 6.51 AGS-004 HIV Phase 2b Phase 2b trial did not meet endpoint – early Jan 2015 1/10/2015 ORPN 7.82 Cabaletta Oculopharyngeal Muscular Dystrophy Phase 2/3 Phase 2/3 HOPEMD […]

Read more

NBIX meets Phase 3 endpoint + updates for ALNY CNAT CYTR PLX GALE GWPH INFI IXPL KMDA LGND OTIC RGLS SGYP VSAR VSTM

Jan 09, 2015 No Comments

Latest updates to the Company Pipeline Database from January 8, 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Text Updated ALNY 101.70 Patisiran APOLLO Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR Phase 3 Phase 3 trial initiated Nov 2013, continues to enrol patients as of Nov 2014. Expects […]

Read more